Ipsen
E645749
Ipsen is a global biopharmaceutical company headquartered in France, focused on specialty care areas such as oncology, neuroscience, and rare diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ipsen canonical | 1 |
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| country | France ⓘ |
| focusesOn |
neuroscience
ⓘ
oncology ⓘ rare diseases ⓘ specialty care ⓘ |
| foundedBy | Henri Beaufour NERFINISHED ⓘ |
| hasMajorShareholder | Beaufour family NERFINISHED ⓘ |
| hasOfficeIn |
Australia
NERFINISHED
ⓘ
Canada NERFINISHED ⓘ China NERFINISHED ⓘ Germany NERFINISHED ⓘ Italy NERFINISHED ⓘ Japan NERFINISHED ⓘ Spain NERFINISHED ⓘ United Kingdom NERFINISHED ⓘ United States NERFINISHED ⓘ |
| hasRAndDCenterIn |
France
NERFINISHED
ⓘ
United Kingdom NERFINISHED ⓘ United States NERFINISHED ⓘ |
| hasSubsidiary |
Ipsen Biopharmaceuticals Inc.
NERFINISHED
ⓘ
Ipsen Pharma SAS NERFINISHED ⓘ |
| headquartersLocation | Boulogne-Billancourt, France NERFINISHED ⓘ |
| inception | 1929 ⓘ |
| industry |
biopharmaceuticals
ⓘ
pharmaceuticals ⓘ |
| isListedOn | CAC Mid 60 NERFINISHED ⓘ |
| languageOfWorkOrName |
English
ⓘ
French ⓘ |
| legalForm | Société Anonyme NERFINISHED ⓘ |
| product |
Cabometyx
NERFINISHED
ⓘ
Decapeptyl NERFINISHED ⓘ Dysport NERFINISHED ⓘ Onivyde NERFINISHED ⓘ Somatuline NERFINISHED ⓘ |
| researchFocus |
innovative medicines
ⓘ
neuroscience ⓘ oncology ⓘ rare diseases ⓘ |
| stockExchange | Euronext Paris NERFINISHED ⓘ |
| therapeuticArea |
endocrine tumors
ⓘ
gastroenteropancreatic neuroendocrine tumors ⓘ movement disorders ⓘ neurotoxin treatments ⓘ prostate cancer ⓘ spasticity ⓘ |
| tickerSymbol | IPN NERFINISHED ⓘ |
| website | https://www.ipsen.com ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.